Liver Diseases pp 687-694 | Cite as

New Loco Regional Approaches to Treat Liver Cancer

  • Shaikh Afaq
  • Jayesh M. Soni
  • Anil K. PillaiEmail author


Hepatocellular carcinoma is the third most common cause of cancer related death worldwide. The only curative treatment of HCC is liver transplantation. Curative intent treatment with surgical resection does not offer protection against developing new tumors in the background of ongoing cirrhosis. Only about 20% of patients are candidates for surgical treatments due to poor hepatic reserve, multifocal disease or shortage of donor organs. Loco regional palliation with interventional radiology techniques have become the mainstay in the management of these patients (Golabi et al., Medicine 96(9): e5904, 2017). Systemic therapy offers modest benefit for patients who are not candidates for loco regional treatments. Novel approaches including tumor ablation and endovascular embolization will be discussed in this chapter with specific focus on mechanism of action, indications, overview of procedure and outcomes (Raza and Sood, World Journal of Gastroenterology 20(15): 4115–4127, 2014).


Hepatocellular carcinoma (HCC) Barcelona clinic liver cancer BCLC Percutaneous ethanol injection (PEI) Radiofrequency ablation (RFA) Microwave ablation (MWA) Cryoablation Irreversible Electroporation (IRE) Trans-arterial embolization (TAE) Trans-arterial chemoembolization (TACE) Drug eluting beads (DEBs) Yttrium 90 (Y-90) Immunotherapy Stereotactic radiation 


  1. 1.
    Golabi P, Fazel S, Otgonsuren M, et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine. 2017;96(9):e5904.CrossRefGoogle Scholar
  2. 2.
    Ramesh H. Resection for Hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(3):S90–6.CrossRefGoogle Scholar
  3. 3.
    Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115–27.CrossRefGoogle Scholar
  4. 4.
    Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: where are we? World J Exp Med. 2016;6(1):21–36.CrossRefGoogle Scholar
  5. 5.
    Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy. a unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Rentgenol Diagn Imag Relat Sci. 2000;174(2):323.Google Scholar
  6. 6.
    Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver. 2010;4(1):S113–8.CrossRefGoogle Scholar
  7. 7.
    Poggi G, Tosoratti N, Montagna B, et al. Microwave ablation of hepatocellular carcinoma. World J Hepatol. 2015;7(25):2578–89.CrossRefGoogle Scholar
  8. 8.
    Liu CH, Yu CY, Chang WC, et al. Computed tomographic-guided percutaneous radiofrequency ablation with hydro dissection of hepatic malignancies in the Subcapsular location: evaluation of safety and technical efficacy. J Chin Med Assoc. 2016;79(2):93–100.CrossRefGoogle Scholar
  9. 9.
    Pillai K, Akhter J, Chua TC, et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine. 2015;94(9):e580.CrossRefGoogle Scholar
  10. 10.
    Rhim H, Lim HK, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. World J Gastrointest Surg. 2010;2(4):128–36.CrossRefGoogle Scholar
  11. 11.
    Lu MD, Chen JW, Xie XY, et al. Hepatocellular carcinoma: US guided percutaneous microwave coagulation therapy. Radiology. 2001;221(1):167–72.CrossRefGoogle Scholar
  12. 12.
    Lu MD, Xu HX, Xie XY, et al. Percutaneous microwave and radiofrequency ablation for Hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40(11):1054–60.CrossRefGoogle Scholar
  13. 13.
    Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009;115(9):1914–23.CrossRefGoogle Scholar
  14. 14.
    Doo Song K. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol. 2016;22(4):509–15.CrossRefGoogle Scholar
  15. 15.
    Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous Cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61(5):1579–90.CrossRefGoogle Scholar
  16. 16.
    Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of HCC: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:49–58.CrossRefGoogle Scholar
  17. 17.
    Song MJ, Bae SH, Lee JS, et al. Combination trans arterial chemoembolization and radiofrequency ablation therapy for early HCC. Korean J Intern Med. 2016;31(2):242–52.CrossRefGoogle Scholar
  18. 18.
    Song JE, Kim DY. Conventional versus drug-eluting beads TACE for HCC. World J Hepatol. 2017;9(18):808–14.CrossRefGoogle Scholar
  19. 19.
    Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with Doxorubicin-eluting beads for Intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64(5):1090–8.CrossRefGoogle Scholar
  20. 20.
    Tzochatzis EA, Fatourou E, O’Birne J, et al. TACE and bland embolization for HCC. World J Gastroenterol. 2014;20(12):3069–77.CrossRefGoogle Scholar
  21. 21.
    Osuga K, Hori S, Hirasishi K, et al. Bland embolization of HCC using superabsorbent polymer microspheres. Cardiovasc Intervent Radiol. 2008;31(6):1108–16.CrossRefGoogle Scholar
  22. 22.
    Kallini JR, Gabr A, Salem R, et al. Trans arterial radio embolization with yttrium-90 for the treatment of HCC. Adv Ther. 2016;33:669–714.CrossRefGoogle Scholar
  23. 23.
    Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable HCC: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2):S107–10.CrossRefGoogle Scholar
  24. 24.
    Geschwind JF, Salem R, Carr BI, et al. Yttrium 90 microspheres for the treatment of HCC. Gastroenterology. 2004;127(5):S194–205.CrossRefGoogle Scholar
  25. 25.
    Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific Patients with HCC. J Clin Oncol. 2018;36(19):1913–21.CrossRefGoogle Scholar
  26. 26.
    Pardee AD, Butterfield LH. Immunotherapy of HCC. Oncoimmunology. 2012;1(1):48–55.CrossRefGoogle Scholar
  27. 27.
    Katsanos K, Kitrou P, Spiliopoulos S, et al. Comparative effectiveness of different trans-arterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable HCC: a network meta-analysis of randomized controlled trials. PLoS One. 2017;12(9):e0184597.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of Texas Health Science CenterHoustonUSA
  2. 2.Diagnostic and Interventional ImagingUniversity of Texas Health Science CenterHoustonUSA

Personalised recommendations